Notice: This company has been marked as potentially delisted and may not be actively trading. Ritter Pharmaceuticals (RTTR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends RTTR vs. PCRX, CDMO, IMNM, TRDA, NUVB, MBX, ORIC, STOK, ANNX, and ABUSShould you be buying Ritter Pharmaceuticals stock or one of its competitors? The main competitors of Ritter Pharmaceuticals include Pacira BioSciences (PCRX), Avid Bioservices (CDMO), Immunome (IMNM), Entrada Therapeutics (TRDA), Nuvation Bio (NUVB), MBX Biosciences (MBX), ORIC Pharmaceuticals (ORIC), Stoke Therapeutics (STOK), Annexon (ANNX), and Arbutus Biopharma (ABUS). These companies are all part of the "medical" sector. Ritter Pharmaceuticals vs. Pacira BioSciences Avid Bioservices Immunome Entrada Therapeutics Nuvation Bio MBX Biosciences ORIC Pharmaceuticals Stoke Therapeutics Annexon Arbutus Biopharma Pacira BioSciences (NASDAQ:PCRX) and Ritter Pharmaceuticals (NASDAQ:RTTR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, community ranking, institutional ownership, media sentiment, dividends, valuation and profitability. Does the MarketBeat Community favor PCRX or RTTR? Pacira BioSciences received 521 more outperform votes than Ritter Pharmaceuticals when rated by MarketBeat users. Likewise, 71.57% of users gave Pacira BioSciences an outperform vote while only 70.23% of users gave Ritter Pharmaceuticals an outperform vote. CompanyUnderperformOutperformPacira BioSciencesOutperform Votes82371.57% Underperform Votes32728.43% Ritter PharmaceuticalsOutperform Votes30270.23% Underperform Votes12829.77% Do institutionals and insiders believe in PCRX or RTTR? 99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 0.8% of Ritter Pharmaceuticals shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Comparatively, 15.4% of Ritter Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, PCRX or RTTR? Pacira BioSciences has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Ritter Pharmaceuticals has a beta of -0.43, indicating that its share price is 143% less volatile than the S&P 500. Is PCRX or RTTR more profitable? Ritter Pharmaceuticals has a net margin of 0.00% compared to Pacira BioSciences' net margin of -13.07%. Pacira BioSciences' return on equity of 13.42% beat Ritter Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Pacira BioSciences-13.07% 13.42% 7.19% Ritter Pharmaceuticals N/A N/A -162.05% Which has preferable earnings & valuation, PCRX or RTTR? Pacira BioSciences has higher revenue and earnings than Ritter Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPacira BioSciences$694.96M1.11$41.96M-$2.03-8.20Ritter PharmaceuticalsN/AN/A-$10.13MN/AN/A Does the media refer more to PCRX or RTTR? In the previous week, Pacira BioSciences had 8 more articles in the media than Ritter Pharmaceuticals. MarketBeat recorded 8 mentions for Pacira BioSciences and 0 mentions for Ritter Pharmaceuticals. Pacira BioSciences' average media sentiment score of 0.63 beat Ritter Pharmaceuticals' score of 0.00 indicating that Pacira BioSciences is being referred to more favorably in the media. Company Overall Sentiment Pacira BioSciences Positive Ritter Pharmaceuticals Neutral Do analysts rate PCRX or RTTR? Pacira BioSciences presently has a consensus target price of $23.50, suggesting a potential upside of 41.23%. Given Pacira BioSciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Pacira BioSciences is more favorable than Ritter Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pacira BioSciences 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.20Ritter Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryPacira BioSciences beats Ritter Pharmaceuticals on 13 of the 16 factors compared between the two stocks. Ad Behind the Markets📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Take these 4 steps to protect your retirement here >>> Get Ritter Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTTR vs. The Competition Export to ExcelMetricRitter PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$168.00M$6.77B$5.17B$8.75BDividend YieldN/A8.21%7.61%4.06%P/E Ratio-5.6911.19120.2417.57Price / SalesN/A359.921,370.0991.65Price / CashN/A50.7538.3535.22Price / Book36.409.726.425.89Net Income-$10.13M$152.49M$117.52M$225.22M Ritter Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTTRRitter PharmaceuticalsN/A$3.64+1.1%N/A+393.2%$168.00MN/A-5.697PCRXPacira BioSciences3.8972 of 5 stars$16.94-3.2%N/A-40.5%$782.12M$674.98M-8.34720Gap DownCDMOAvid Bioservices3.6199 of 5 stars$12.24-0.1%N/A+118.7%$780.79M$139.91M-5.39371Positive NewsIMNMImmunome1.7251 of 5 stars$12.79-3.5%N/A+24.0%$768.04M$14.02M-1.6640Analyst RevisionNews CoverageGap UpTRDAEntrada Therapeutics2.2799 of 5 stars$19.57-1.6%N/A+10.0%$732.31M$215.23M12.31110NUVBNuvation Bio2.3467 of 5 stars$2.92-3.0%N/A+90.6%$727.80M$2.16M-1.3560MBXMBX Biosciences1.9234 of 5 stars$22.68-3.5%N/AN/A$722.36MN/A0.0036News CoverageGap UpORICORIC Pharmaceuticals4.2326 of 5 stars$10.22-0.8%N/A+24.3%$720.94MN/A-5.8480Earnings ReportAnalyst RevisionGap UpSTOKStoke Therapeutics3.8792 of 5 stars$13.51-2.2%N/A+185.1%$715.63M$8.78M-6.43100ANNXAnnexon2.8584 of 5 stars$6.64-4.7%N/A+135.4%$701.52MN/A-5.4060Analyst ForecastShort Interest ↓Analyst RevisionGap UpABUSArbutus Biopharma2.8279 of 5 stars$3.68-1.3%N/A+95.7%$697.32M$18.14M-8.5673Analyst ForecastShort Interest ↓News Coverage Related Companies and Tools Related Companies Pacira BioSciences Competitors Avid Bioservices Competitors Immunome Competitors Entrada Therapeutics Competitors Nuvation Bio Competitors MBX Biosciences Competitors ORIC Pharmaceuticals Competitors Stoke Therapeutics Competitors Annexon Competitors Arbutus Biopharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RTTR) was last updated on 11/18/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | SponsoredThe Stock Powering Musk’s AI Revolution—RevealedImagine being able to invest in Tesla, PayPal, or SpaceX before the world knew their potential. Today, you ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ritter Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ritter Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
